Alpine Immune Sciences's revenue for the
three
months ended in Dec. 2023 was $30.85 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $58.88 Mil.
Alpine Immune Sciences's Revenue per Share for the
three
months ended in Dec. 2023 was $0.56.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.14.
Warning Sign:
Alpine Immune Sciences Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Alpine Immune Sciences was 31.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 38.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 93.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, Alpine Immune Sciences's highest 3-Year average Revenue per Share Growth Rate was 162.30% per year. The lowest was 18.80% per year. And the median was 74.75% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alpine Immune Sciences's Revenue
For the Biotechnology subindustry, Alpine Immune Sciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpine Immune Sciences's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Revenue distribution charts can be found below:
* The bar in red indicates where Alpine Immune Sciences's Revenue falls into.
Alpine Immune Sciences Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $58.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Alpine Immune Sciences Revenue Related Terms
Thank you for viewing the detailed overview of Alpine Immune Sciences's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alpine Immune Sciences (Alpine Immune Sciences) Business Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALPN has been successfully added to your 